Amyris, Janssen collaborate biosynthetic drug discovery

Amyris, Janssen collaborate for biosynthetic drug discovery

10:55 AM, 7th June 2016
Amyris, Janssen collaborate for biosynthetic drug discovery

EMERYVILLE, US: Amyris Inc has entered into a research agreement with a commercial license option with Janssen Biotech Inc, part of Janssen Pharmaceutical Companies.

Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, the collaboration will use Amyris’s µPharm platform technology to develop a customized library of natural and natural-like compounds to test against Janssen’s therapeutic target.

Nature has been a great source for therapeutics, ranging from antibiotics to statins that lower cholesterol levels; however, Nature’s potential is often under-utilized due to scarcity or unavailability. Amyris’s µPharm platform technology enables an integrated discovery and production process for therapeutic compounds. It not only provides access to scarce natural compounds, but also creates new diversity based on natural compound scaffolds.

Over the course of the agreement, Amyris will utilize the µPharm platform technology to develop a library of natural and natural-like compounds and test the efficacy of those compounds in vivo for hits against Janssen’s identified target.

This is a different approach than traditional high throughput screening, which typically applies thousands of chemical compounds in vitro screens to find a drug candidate. Instead, the µPharm platform starts with the target, identifies candidate natural compound structures, and then creates diversity around those structures for in vivo testing. The result can lead to increased speed and enhanced efficiency in identifying hits while accelerating the time to market commercialization.

“We’re pleased to add another strong partner to our collaboration portfolio and this agreement is consistent with our overall business model of upfront development investment by a partner and an opportunity for a long term revenue stream following successful commercialization,” said Cynthia Bryant, Amyris senior VP corporate development & collaborations. “This technology opens a new area of compounds that have never been accessible for new drug discovery.”

“We are helping to take some of the guess work out of new drug discovery, which helps our partners, like Janssen, to be able to more quickly understand target interaction and ultimately discover new therapies faster,” explained Joel Cherry, Amyris’s president, research and development.

“Janssen has a successful history of identifying and tapping into new innovation through collaborations. They are an ideal partner for Amyris to demonstrate the benefits of our µPharm platform technology while improving the health of everyone in the world,” stated Bryant.

© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Scientists use silver to make lights shine brightly

LONDON, UK: The toxic and expensive phosphors used widely in fluorescent lighting could be eliminated thanks to a new study conducted by a materials s ...

Read more
Vikas Ecotech, Nafigate to produce bioplastics from waste cooking oil

MUMBAI, INDIA: Vikas Ecotech Ltd (formerly Vikas Global One Ltd) has signed an memorandum of understanding (MoU) with Czech Republic based Nafigate Co ...

Read more
A new approach to chemical synthesis

CAMBRIDGE, US: MIT chemists have devised a new way to synthesize a complex molecular structure that is shared by a group of fungal compounds with pote ...

Read more
BASF postpones US plant expansion project

LUDWIGSHAFEN, GERMANY/FREEPORT, US: BASF SE has postponed its final investment decision regarding the construction of a methane-to-propylene complex a ...

Read more
Scientists fix broken bonds, leading to efficient catalyst for biofuel production

RICHLAND, US: While popular catalysts called zeolites could help turn paper manufacturing waste and other biomass into fuel, the catalyst crumbles aft ...

Read more
BASF expands Laromer UV/EB acrylates capacity in Germany

LUDWIGSHAFEN, GERMANY: BASF SE expands its existing production facilities for Laromer UV/EB acrylates, which are part of BASF’s C3-Verbund syste ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X